  available SBIR/STTR set-aside funds on the basis of scientific and technical        
  merit and commercial potential of the proposed research, program relevance, and     
  program balance among the areas of research.                                        
Deadlines:                                                                            
  New Grants: February 1, June 1, and October 1. Renewals and Supplements:            
  March 1, July 1, and November 1. Cooperative Agreements are usually                 
  submitted in response to a Request for Applications (RFA). The receipt date is      
  stipulated in the RFA. SBIR: April 15, August 15, and December 15. STTR             
  Grants: April 1, August 1, and December 1.                                          
Range of Approval/Disapproval Time:                                                   
  Approximately 10 months. SBIR Applications: About 7-1/2 months.                     
Appeals:                                                                              
  A principal investigator (P.I.) may question the substantive or procedural aspects  
  of the review of his/her application with the staff of the Institute. A description 
  of the NIH Peer Review Appeal procedures is available on the NIH home page          
  http//grants2.nih.gov/grants/guide/notice-files/not97-232.html.                     
Renewals:                                                                             
  Applications submitted for renewal are reviewed and selected for funding on a       
  competitive basis.                                                                  
Formula and Matching Requirements:                                                    
  This program has no statutory formula or matching requirements.                     
Length and Time Phasing of Assistance:                                                
  Grants and cooperative agreements: Average 3 to 4 years, maximum of 5 years.        
  Renewals may be awarded for additional periods of up to 5 years based on            
  competitive peer review. Funds are provided through Monthly Demand                  
  Payment System or an Electronic Transfer System. SBIR: Normally, Phase I            
  awards are for 6 months; normally, Phase II awards are for 2 years. STTR:           
  Normally, Phase I awards are for 1 year; normally, Phase II awards are for 2        
  years.                                                                              
Reports:                                                                              
  Progress reports are required each year. An Annual financial status report is       
  required 90 days after the end of the budget period. Special reports may be         
  requested by the DHHS. Terminal reports are required 6 months after the end of      
  the project.                                                                        
Audits:                                                                               
  In accordance with the provisions of OMB Circular No. A-133 (Revised, June          
  27, 2003), "Audits of States, Local Governments, and Nonprofit Organizations",      
  nonfederal entities that expend financial assistance of $500,000 or more in         
  Federal awards will have a single or a program-specific audit conducted for that    
  year. Nonfederal entities that expend less than $500,000 a year in Federal          
  awards are exempt from Federal audit requirements for that year, except as noted    
  in Circular No. A-133. In addition, grants and cooperative agreements are           
  subject to inspection and audits by DHHS and other Federal government               
  officials.                                                                          
Records:

  Expenditures and other financial records must be retained for 3 years from the

  day on which the grantee submits the last financial status report for the report    
  period.                                                                             
Account Identification:                                                               
  75-0849-0-1-550.                                                                    
Obligations:                                                                          
  (Grants) For RPG: FY 07 $528,525,000; FY 08 est $508,240,000; and FY 09 est         
  $503,576,000. For SBIR/STTR: FY 07 $32,096,000; FY 08 est $31,451,000;              
  and FY 09 est $32,918,000.                                                          
Range and Average of Financial Assistance:                                            
  $36,048 to $5,296,416; $427,264.                                                    
PROGRAM ACCOMPLISHMENTS:                                                              
  Competing FY 20076 RPG act. 312 awards which were 20.1 percent of                   
  applications received. Competing FY 2007 SBIR/STTR act. 66 awards which             
  were 21.6 percent of applications received. Fiscal year 2008 est. 1,260 total       
  awards and FY 2009 est. 1,227 total awards.                                         
REGULATIONS, GUIDELINES, AND LITERATURE:                                              
  42 CFR 52; 45 CFR 74; 45 CFR 92. Grants will be available under the authority       
  of and administered in accordance with the PHS Grants Policy Statement and          
  Federal regulations at 42 CFR 52 and 42 USC 241; Omnibus Solicitation of the        
  Public Health Service for Small Business Innovation Research (SBIR) Grant and       
  Cooperative Agreement Applications. Omnibus Solicitation of the National            
  Institutes of Health for Small Business Technology Transfer (STTR) Grant            
  Applications.                                                                       
Regional or Local Office:                                                             
  Not applicable.                                                                     
Headquarters Office:                                                                  
  Program Contact: Dr. James H. Doroshow, Director, Division of Cancer                
  Treatment and Diagnosis, National Cancer Institute, National Institutes of          
  Health, Department of Health and Human Services, 9000 Rockville Pike,               
  Building 31/3A44, Bethesda, MD 20892, Telephone (301) 496-4291. Grants              
  Management Contact: Leo F. Buscher, Jr., Grants Management Officer, National        
  Cancer Institute, National Institutes of Health, Department of Health and Human     
  Services, EPS-234, Bethesda, MD 20892, Telephone (301) 496-7753. Use the            
  same numbers for FTS.                                                               


1414                                                                            11-08

Web Site Address:
  http://www.nci.nih.gov.
RELATED PROGRAMS:
  93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and
  Diagnosis Research; 93.396, Cancer Biology Research; 93.399, Cancer Control.
EXAMPLES OF FUNDED PROJECTS:
  Fundamental research projects on problems of anticancer drug discovery and
  development, preclinical biochemistry, pharmacology, cell and molecular
  biology of cancer treatment, and the clinical development and evaluation of all
  modalities of treatment, both alone and in combination. These include surgery,
  radiotherapy, chemotherapy, immunotherapy, cellular therapy, vaccines,
  liposomes, antisense therapy, gene therapy, and supportive approaches
  including: nutritional support and blood component replacement; clinical trials
  after drugs undergo screening, toxicology, and pharmacology testing; and the
  provision of research animals, compounds, and formulated drugs.
CRITERIA FOR SELECTING PROPOSALS:
  The major elements in evaluating applications include assessments of: (1) The
  scientific merit and general significance of the proposed study and its objectives;
  (2) the technical adequacy of the experimental design and approach; (3) the
  competency of the proposed investigator or group to successfully pursue the
  project; (4) the adequacy of the available and proposed facilities and resources;
  (5) the necessity of the budget components requested in relation to the proposed
  project; and (6) the relevance and importance to announced program objectives.
  The following criteria will be used in considering the scientific and technical
  merit of SBIR/STTR Phase I grant applications: (1) The soundness and technical
  merit of the proposed approach; (2) the qualifications of the proposed principal
  investigator, supporting staff, and consultants; (3) the technological innovation
  of the proposed research; (4) the potential of the proposed research for
  commercial application; (5) the appropriateness of the budget requested; (6) the
  adequacy and suitability of the facilities and research environment; and (7)
  where applicable, the adequacy of assurances detailing the proposed means for
  (a) safeguarding human or animal subjects, and/or (b) protecting against or
  minimizing any adverse effect on the environment. Phase II grant applications
  will be reviewed based upon the following criteria: (1) The degree to which the
  Phase I objectives were met and feasibility demonstrated; (2) the scientific and
  technical merit of the proposed approach for achieving the Phase II objectives;
  (3) the qualifications of the proposed principal investigator, supporting staff, and
  consultants; (4) the technological innovation, originality, or societal importance
  of the proposed research; (5) the potential of the proposed research for
  commercial application; (6) the reasonableness of the budget requested for the
  work proposed; (7) the adequacy and suitability of the facilities and research
  environment; and (8) where applicable, the adequacy of assurances detailing the
  proposed means for (a) safeguarding human or animal subjects, and/or (b)
  protecting against or minimizing any adverse effect on the environment.
93.396 CANCER BIOLOGY RESEARCH
FEDERAL AGENCY:
  NATIONAL INSTITUTES OF HEALTH, DEPARTMENT OF HEALTH AND
  HUMAN SERVICES
AUTHORIZATION:
  Public Health Service Act, Section 301, 410, and 411, Public Law 78-410, 42
  U.S.C. 241, as amended; Public Law 100-607, 42 U.S.C. 285 and 285a; Small
  Business Research and Development Enhancement, Act of 1992, as amended,
  Public Law 102-564.
OBJECTIVES:
  To provide fundamental information on the cause and nature of cancer in people,
  with the expectation that this will result in better methods of prevention,
  detection and diagnosis, and treatment of neoplastic diseases. Cancer Biology
  Research includes the following research programs: cancer cell biology, cancer
  etiology, structural biology and molecular applications, DNA and chromosomal
  aberrations, tumor biology and metastasis, and immunology andhematology.
  Small Business Innovation Research (SBIR) program: To expand and improve
  the SBIR program; to increase private sector commercialization of innovations
  derived from Federal participation in Federal research and development; and to
  foster and encourage participation of socially and economically disadvantaged
  small business concerns and women-owned small business concerns in
  technological innovation. Small Business Technology Transfer (STTR)
  program: To stimulate and foster scientific and technological innovation through
  cooperative research and development carried out between small business
  concerns and research institutions; to foster technology transfer; increase private
  sector commercialization of innovations derived from Federal research and
  development; and to foster and encourage participation of socially and
  economically disadvantaged small business concerns and women-owned small
  business concerns in technological innovation.
TYPES OF ASSISTANCE:
  Project Grants.
USES AND USE RESTRICTIONS:
  Grants and cooperative agreements may be made to eligible institutions for the
  support of cancer research projects. The grants and cooperative agreements may
